ARZ-005

ARZ-005 is a **preclinical small-molecule drug candidate** being developed by **Artizan Biosciences** for **inflammatory bowel disease**. Publicly available sources identify it as an internally developed investigational program in Artizan's pipeline, but do not provide a validated disclosure of its precise molecular target, mechanism of action, formulation details, or route of administration. Based on currently accessible information, it should be characterized as an early-stage, non-approved pharmaceutical candidate for immune and gastrointestinal disorders, with inflammatory bowel disease as the most clearly associated indication.